Dr Reddy's Crashes 9% on Q1 FY27 Miss: Semaglutide Costs and US Generic Erosion Create 2-Quarter Earnings Trough

• Quick Take: Dr Reddy's Laboratories shares crashed nearly 9% Thursday after Q1 FY27 showed lower-than-expected revenue alongside sharply compressed margins, with three major brokerages turning bearish.
• The margin pressure was driven by elevated semaglutide API ramp costs and US generic price erosion—two headwinds that analysts see continuing into Q2 FY27.
• The 9% single-day decline is the largest single-session fall for Dr Reddy's in over two years, triggering technical stop-losses and a broader re-rating of India's pharma large-caps.

Dr Reddy's Laboratories (NSE: DRREDDY) suffered one of its worst single-session performances in two years Thursday, with shares plunging nearly 9% after Q1 FY27 results revealed a double disappointment: revenue came in below estimates and margins were compressed by costs that investors had hoped would begin moderating. Two distinct but related headwinds drove the underperformance. First, semaglutide API manufacturing ramp costs hit the P&L as Dr Reddy's scales its peptide synthesis capabilities—an investment that represents a strategic bet on the GLP-1 biosimilar market but creates near-term earnings drag. Second, the North American generics business experienced continued price erosion in the base portfolio, a structural pressure affecting most Indian generics majors competing in the commoditized US market.

The institutional reaction was swift and decisive. Three prominent brokerages downgraded their stance on the stock or reduced price targets, citing the combination of cost escalation and pricing pressure. JM Financial specifically highlighted the semaglutide API investment timeline—noting that the costs are front-loaded but the revenue realization is not expected until FY28-FY29 when GLP-1 biosimilar market opportunities materialize. The bear thesis articulated by sell-side analysts centers on a 2-3 quarter earnings trough where investors must hold through margin depression before the GLP-1 bet either pays off or fails. That patience requirement is not universally shared, particularly by momentum-oriented FII holders who entered the stock on its strong H2 FY26 performance.

The technical damage compounds the fundamental concern. Dr Reddy's is one of India's most widely held pharma blue chips, with significant foreign institutional investor (FII) ownership and inclusion in NSE Nifty 50, making it a forced-sell for passive funds that must rebalance weights. The 9% move wipes out roughly several months of gains and breaks key moving average support levels that technical traders will monitor for stabilization signals. For investors with a longer horizon, the semaglutide positioning—if validated by eventual GLP-1 market entry—represents meaningful upside, but the near-term risk is further downward revision of FY27 consensus EPS estimates as analysts process the Q1 miss.